Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kineta Inc KANT

Healthcare Biotechnology
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a... see more

Recent & Breaking News (OTCPK:KANT)

Proteostasis Therapeutics Announces Progression of PTI-428 and PTI-801 to Longer Duration Studies in CF Subjects

GlobeNewswire July 31, 2017

Proteostasis Appoints Helen M. Boudreau as Chief Financial Officer

GlobeNewswire July 31, 2017

Proteostasis Therapeutics Reports Preliminary Data from Phase 1 Study of PTI-428 in Patients with Cystic Fibrosis

GlobeNewswire June 29, 2017

Proteostasis Therapeutics Files Investigational New Drug Application for PTI-808, Cystic Fibrosis Potentiator

GlobeNewswire June 23, 2017

Proteostasis Therapeutics Announces Clinical and Regulatory Progress Across Pipeline Programs

GlobeNewswire June 7, 2017

Mid-Morning Market Update: Markets Edge Lower; BlackBerry Earnings Top Views

Benzinga.com  March 31, 2017

Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update

GlobeNewswire March 30, 2017

Proteostasis Therapeutics Reports Third Quarter 2016 Financial Results

GlobeNewswire November 10, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Involving Possible Securities Fraud Violations by Proteostasis Therapeutics, Inc. and Certain of Its Officers and Directors

Business Wire October 28, 2016

Proteostasis Therapeutics Announces Conference Call to Provide Clinical and Scientific Update at 30th Annual North American Cystic Fibrosis Conference

GlobeNewswire October 26, 2016

Proteostasis Therapeutics Appoints Naimish Patel, M.D., C.M., and Elizabeth Tullis, M.D., FRCPC, to its Clinical Advisory Board

GlobeNewswire September 28, 2016

Proteostasis Therapeutics Announces Scientific Presentations on New Data at 30th Annual North American Cystic Fibrosis Conference

GlobeNewswire September 22, 2016

Proteostasis Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire September 15, 2016

Proteostasis Therapeutics Announces Closing of Follow-On Public Offering of Common Stock

GlobeNewswire September 14, 2016

Proteostasis Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire September 9, 2016

Analysts Are Bullish On These 5 Stocks That Went Public This Year

Benzinga.com  August 13, 2016

Proteostasis Therapeutics Issues Mid-Year Corporate Update on Cystic Fibrosis Pipeline Programs

GlobeNewswire August 11, 2016

Proteostasis Therapeutics Achieves Preclinical Milestone in Astellas Pharma Collaboration

GlobeNewswire August 8, 2016

Proteostasis Therapeutics Announces Key Leadership Appointments

GlobeNewswire August 8, 2016

Proteostasis Therapeutics, Inc. Presents New Data Demonstrating Potential for Genotype-Agnostic and Combination Therapies for People with Cystic Fibrosis

GlobeNewswire March 30, 2016